Colorectal Cancer

Thierry André, MD, discusses findings from the phase 3 CheckMate 8HW trial of nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Kanwal P.S. Raghav, MBBS, MD, details the preliminary safety of a ABBV-400 regimen for the treatment of patients with previously treated mCRC.

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

China’s NMPA has granted priority review to an NDA for neoadjuvant ipilimumab injection plus sintilimab in MSI-H or dMMR colon cancer.

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.